Showing 1 - 1 of 1 Endometrial Cancers
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (NRG-GY018)

Status: Enrolling

Investigator: Tarrik Zaid

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recur ... Read more >